Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/34465
Title: Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
Authors: LEYLAND, NicholasTAYLOR, Hugh S.ARCHER, David F.PELOSO, Paul M.SOLIMAN, Ahmed M.PALAC, Hannah L.MARTINEZ, MarisolABRAO, Mauricio S.
Citation: JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS, v.11, n.4, p.171-180, 2019
Abstract: Objectives: The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain. Methods: Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies (Elaris Endometriosis-I and Elaris Endometriosis-II) of elagolix at two doses (150 mg QD and 200 mg BID) in women with endometriosis-associated pain. In this post hoc analysis, dyspareunia responders were defined as having a clinically meaningful decrease from baseline in the dyspareunia score and decreased or stable use of rescue analgesic agents, as recorded in a daily electronic diary. Sexual relationship was assessed using the 30-item Endometriosis Health Profile questionnaire sexual relationship module. Results: A total of 1384 women reported > 1 day of sexual activity at baseline (35 days prior to and including day 1 of treatment). Of these 1384 women, 1297 (94%) reported > 1 day of any dyspareunia (mild, moderate, or severe), of which 51% reported > 1 day of severe dyspareunia. Among sexually active women who reported any dyspareunia at baseline, both elagolix doses led to improvements in dyspareunia. Women in the 200-mg BID group showed more months at which the dyspareunia response rates were statistically significantly greater than placebo, particularly in a subgroup of women with severe dyspareunia at baseline. Compared to placebo, both elagolix doses led to statistically significantly greater improvements in the mean 30-item Endometriosis Health Profile sexual relationship module score. Conclusion: Up to 6 months of elagolix treatment improved dyspareunia in women with endometriosis-associated pain in a dose-dependent manner, with 200-mg BID dose showing the most significant improvements in dyspareunia and quality of sexual relationships compared with placebo.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MOG
Departamento de Obstetrícia e Ginecologia - FM/MOG

Artigos e Materiais de Revistas Científicas - LIM/58
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular


Files in This Item:
File Description SizeFormat 
art_LEYLAND_Elagolix_reduced_dyspareunia_and_improved_healthrelated_quality_of_2019.PDF
  Restricted Access
publishedVersion (English)584.93 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.